Q3 Domestic PDT revenues up 32% year over year; Q3 Non-GAAP loss
improves 86% year over year to ($0.2) million WILMINGTON, Mass.,
Nov. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.®
(Nasdaq GM: DUSA), a dermatology company that is developing and
marketing Levulan® Photodynamic Therapy (PDT) and other products
focused on patients with common skin conditions, reported today its
corporate highlights and financial results for the third quarter
ended September 30, 2009. Third quarter and year-to-date financial
highlights include: -- Domestic PDT revenues totaled $6.2 million
for the third quarter of 2009, representing a $1.5 million, or 32%,
improvement as compared to the third quarter of 2008. Year-to-date
2009 domestic PDT revenues totaled $18.7 million, representing a
$3.8 million, or 25%, improvement year over year. -- Domestic
Kerastick® revenues totaled $5.8 million for the third quarter of
2009, representing a $1.4 million, or 32%, improvement as compared
to the third quarter of 2008. Year-to-date 2009 domestic Kerastick®
revenues totaled $17.1 million, representing a $3.4 million, or
25%, improvement year over year. -- Domestic BLU-U® revenues
totaled $0.5 million for the third quarter of 2009, representing a
$0.1 million, or 22%, improvement as compared to the third quarter
of 2008. Year-to-date 2009 domestic BLU-U® revenues totaled $1.6
million, representing a $0.4 million, or 32%, improvement year over
year. -- Kerastick® gross margins for the third quarter of 2009
reached a record high of 86%. -- Non-GAAP loss for the third
quarter of 2009 improved 86% year over year, and narrowed to $0.2
million. Management Comments: "We are excited to report the
improvement in many of our key financial indicators this quarter,"
stated Robert Doman, President and CEO. "The combination of strong
top line PDT revenue growth, the achievement of record Kerastick
margins, and reductions in our overall spending drove our non-GAAP
loss to a record low point." "We experienced significant growth in
Kerastick revenue during the third quarter. This is due in part to
solid execution by the sales and marketing team and a 33% increase
in BLU-U volume year-to-date. This represents the 16th consecutive
quarter of year over year domestic Kerastick growth." "In October,
we announced an important milestone in the Company's history,
having surpassed cumulative Kerastick sales of one million units.
The achievement of this milestone demonstrates the relevance that
PDT is gaining in the medical dermatology community," continued
Doman. "For the remainder of the year, we will focus our efforts on
further capitalizing on the significant growth potential that
exists for Levulan PDT in the treatment of actinic keratoses
(AKs)," concluded Doman. Third Quarter 2009 Financial Results:
Total product revenues were $6.9 million in the third quarter of
2009, up 21% from $5.7 million in the third quarter of 2008. PDT
revenues totaled $6.7 million, up $1.5 million, or 30%, from $5.2
million for the comparable 2008 period. The increase in PDT
revenues was attributable to a 32% increase in Kerastick® revenues
and a 7% increase in BLU-U® revenues. The Kerastick® revenue
improvement was driven by a 20% increase in our domestic Kerastick®
volume and an overall 10% increase in our average selling price.
Kerastick® sales volumes increased to 53,622 in the third quarter
of 2009 from 44,668 units sold in the third quarter of 2008.
Domestic Kerastick® sales volumes increased by 7,938 units, or 20%,
and were supplemented by a 1,016 unit increase in our international
sales volumes. The BLU-U® revenue increase was driven by a 4%
increase in sales volume. There were 59 units sold during the
quarter, as compared to the prior year quarterly total of 57 units.
Non-PDT revenues totaled $0.2 million versus $0.6 million for the
comparable 2008 period. Non-PDT revenues were adversely impacted by
the absence of Nicomide® royalty revenues in 2009. DUSA has not
received the installment payments due under its exclusive Nicomide®
patent license agreement with River's Edge since June 2009. The
Company is currently evaluating its options to collect the amounts
due from River's Edge. DUSA's net loss on a GAAP basis for the
third quarter of 2009 was ($0.4) million, or ($0.02) per common
share, compared to a net loss of ($2.8) million, or ($0.12) per
common share, in the third quarter of 2008. DUSA's non-GAAP net
loss for the third quarter of 2009, after adjustments for
stock-based compensation expense, consideration provided to the
former Sirius shareholders, and the non-cash change in fair value
of warrants, was ($0.2) million, or ($0.01) per common share,
compared to a net loss of ($1.6) million, or ($0.07) per common
share, in the prior year period. The decrease in the Company's net
loss was primarily the result of the year over year increase in our
PDT revenues and lower operating costs due to the absence of
spending on our Phase IIb acne clinical trial which concluded in
2008. Please refer to the section entitled "Use of Non-GAAP
Financial Measures" and the accompanying financial table included
at the end of this release for a reconciliation of GAAP to non-GAAP
results for the three and nine month periods ending September 30,
2008 and 2009, respectively. Year-to-Date 2009 Financial Results:
Total product revenues for the nine month period ended September
30, 2009 were $21.0 million, down 3% from $21.8 million in
comparable prior year period. PDT revenues totaled $19.8 million,
up $3.4 million, or 21% from $16.4 million for the comparable 2008
period. The increase in PDT revenues was attributable to a 20%
increase in Kerastick® revenues and a 26% increase in BLU-U®
revenues. The Kerastick® revenue improvement was driven by a 13%
increase in our domestic Kerastick® volume and an overall 13%
increase in our average selling price. Kerastick® sales volumes
increased to 155,384 in 2009 from 145,256 units sold in 2008.
Domestic Kerastick® sales volumes increased by 15,966 units, or
13%, and were partially offset by a 5,838 unit decrease in our
international sales volumes. The BLU-U® revenue increase was driven
by a 29% increase in sales volume. There were 198 units sold during
in 2009, representing a 44 unit increase over the prior year total
of 154 units. Non-PDT revenues totaled $1.2 million versus $5.4
million for the comparable 2008 period. Non-PDT revenues were
adversely impacted by the absence of Nicomide® sales in 2009. In
response to discussions with the Food and Drug Administration (FDA)
regarding our marketing of certain products considered by the FDA
to be marketed unapproved drugs, the Company stopped shipping
Nicomide® into the wholesale channel in June of 2008. DUSA's net
loss on a GAAP basis for the nine months ended September 30, 2009
was ($2.9) million or ($0.12) per common share, compared to a net
loss of ($4.3) million or ($0.18) per common share in 2008. DUSA's
non-GAAP net loss, after adjustments for stock-based compensation
expense, a milestone payment made related to the Sirius
acquisition, consideration provided to the former Sirius
shareholders, and the non-cash change in fair value of warrants,
for the nine months ending September 30, 2009 was ($1.9) million,
or ($0.08) per common share, in 2009, compared to ($2.5) million,
or ($0.10) per common share, in 2008. The decrease in our net loss
was primarily the result of the year over year decrease in our
operating costs due mainly to the absence of spending on our Phase
IIb acne clinical trial which concluded in 2008, and a Prescription
Drug User Fee Act (PDUFA) charge accrued in the prior year period.
As of September 30, 2009, total cash, cash equivalents, and
marketable securities were $15.0 million, compared to $18.9 million
at December 31, 2008. Other Updates: -- Solid Organ Transplant
Recipients Clinical Development. -- In May 2009, the Company
announced the initiation of its Phase II clinical trial that is
examining the safety and efficacy of PDT for the treatment of broad
area AKs and the prevention of squamous cell carcinomas in high
risk chronically immunosuppressed solid organ transplant
recipients. All seven clinical sites have been initiated and trial
enrollment is currently underway. -- In May 2008, DUSA filed an
Orphan Drug Designation application with the FDA with respect to
the prevention of cancer occurrence in these patients. The Company
received initial correspondence that the application was not
granted on the basis that the agency believes that the prevalence
of the target population with the disease state is greater than
200,000, which is the maximum number of patients allowed under the
Orphan Drug legislation. During the third quarter of 2009, DUSA met
with the FDA to clarify and explain in more detail our rationale
for the application and, based on that meeting, the agency has
invited us to submit an amendment to our application for further
evaluation. DUSA is in the process of drafting the amendment and
expects to submit it to the FDA later this month. -- BLU-U® Claims
Expansion. -- In May 2009, the Company filed a 510(k) application
with the FDA to expand the allowed claims on BLU-U® to include
severe acne. The filing was based on the results of our Phase IIb
clinical trial. We received a response to our application from the
FDA in June 2009. The agency requested additional information in
order to complete its review of our application, including
supplementary clinical data in support of our claims. Based on the
FDA's requests and the anticipated costs of additional clinical
trials, the Company has decided not to pursue the 510(k)
application for an expansion of the BLU-U® claims at this time.
Revenues Table, Condensed Consolidated Balance Sheets, Condensed
Consolidated Statement of Operations and GAAP to Non-GAAP
reconciliation follow: Revenues for the three month and nine month
periods were comprised of the following: Three-months ended
Nine-months ended September 30, September 30, 2009 2008 2009 2008
(Unaudited) (Unaudited) (Unaudited) (Unaudited) PDT Drug &
Device Product Revenues Kerastick(R) Product Revenues: United
States $5,790,000 $4,374,000 $17,096,000 $13,720,000 Canada 162,000
72,000 404,000 449,000 Korea 201,000 186,000 498,000 710,000 Other
91,000 99,000 261,000 289,000 Subtotal Kerastick(R) Product
Revenues 6,244,000 4,731,000 18,259,000 15,168,000 BLU-U(R) Product
Revenues: United States 456,000 376,000 1,577,000 1,198,000 Korea -
50,000 - 50,000 Subtotal BLU-U(R) Product Revenues 456,000 426,000
1,577,000 1,248,000 Total PDT Drug & Device Product Revenues
6,700,000 5,157,000 19,836,000 16,416,000 Total Non-PDT Product
Revenues 230,000 569,000 1,198,000 5,352,000 TOTAL PRODUCT REVENUES
$6,930,000 $5,726,000 $21,034,000 $21,768,000 DUSA Pharmaceuticals,
Inc. Condensed Consolidated Balance Sheets September 30, December
31, 2009 2008 (Unaudited) -------------------------- ASSETS CURRENT
ASSETS Cash and cash equivalents $5,016,994 $3,880,673 Marketable
securities 10,012,948 15,002,830 Accounts receivable, net 2,519,214
2,367,803 Inventory 2,336,167 2,812,825 Prepaid and other current
assets 1,647,408 1,873,801 --------- --------- TOTAL CURRENT ASSETS
21,532,731 25,937,932 Restricted cash 174,170 173,844 Property,
plant and equipment, net 1,721,488 1,937,978 Deferred charges and
other assets 68,099 160,700 ------ ------- TOTAL ASSETS $23,496,488
$28,210,454 =========== =========== LIABILITIES AND SHAREHOLDERS'
EQUITY CURRENT LIABILITIES Accounts payable $188,417 $305,734
Accrued compensation 889,230 1,515,912 Other accrued expenses
2,343,822 3,226,571 Deferred revenue 1,045,505 611,602 ---------
------- TOTAL CURRENT LIABILITIES 4,466,974 5,659,819 Deferred
revenues 3,061,700 4,157,305 Warrant liability 474,137 436,458
Other liabilities 133,544 244,673 ------- ------- TOTAL LIABILITIES
8,136,355 10,498,255 SHAREHOLDERS' EQUITY Capital stock Authorized:
100,000,000 shares; 40,000,000 shares designated as common stock,
no par, and 60,000,000 shares issuable in series or classes; and
40,000 junior Series A preferred shares. Issued and outstanding:
24,108,908 and 24,089,452 shares of common stock, no par, at
September 30, 2009 and December 31, 2008, respectively 151,683,399
151,663,943 Additional paid-in capital 8,122,801 7,514,900
Accumulated deficit (144,725,805) (141,850,925) Accumulated other
comprehensive loss 279,738 384,281 TOTAL SHAREHOLDERS' EQUITY
15,360,133 17,712,199 ---------- ---------- TOTAL LIABILITIES AND
SHAREHOLDERS' EQUITY $23,496,488 $28,210,454 ===========
=========== DUSA Pharmaceuticals, Inc. Consolidated Statement of
Operations Three-months ended Nine-months ended September 30,
September 30, 2009 2008 2009 2008 (Unaudited) (Unaudited)
(Unaudited) (Unaudited) Product revenues $6,930,110 $5,726,071
$21,033,920 $21,767,810 Cost of product revenues and royalties
1,594,692 1,462,028 4,973,782 4,950,039 Gross margin 5,335,418
4,264,043 16,060,138 16,817,771 Operating costs: Research and
development 963,245 1,487,816 3,225,049 5,049,327 Marketing and
sales 3,013,351 2,967,431 9,460,766 9,520,865 General and
administrative 1,877,928 1,911,028 6,360,325 6,603,989 Impairment
charge for contingent consideration - 1,500,000 - 1,500,000
Settlements, net - 650 75,000 (282,775) Total operating costs
5,854,524 7,866,925 19,121,140 22,391,406 Loss from operations
(519,106) (3,602,882) (3,061,002) (5,573,635) Other income: Other
income, net 79,815 114,260 223,801 538,212 Gain/(loss) on change in
fair value of warrants 24,051 651,767 (37,679) 775,636 Net loss
$(415,240) $(2,836,855) $(2,874,880) $(4,259,787) Basic and diluted
net loss per common share $(0.02) $(0.12) $(0.12) $(0.18) Weighted
average number of common shares 24,108,908 24,078,610 24,099,786
24,078,546 Use of Non-GAAP Financial Measures In addition to
reporting financial results in accordance with GAAP, DUSA has
provided in the table below non-GAAP financial measures adjusted to
exclude stock-based compensation expense, consideration provided to
the former Sirius shareholders, and the non-cash change in fair
value of warrants. The Company believes that this presentation is
useful to help investors better understand DUSA's financial
performance, competitive position and prospects for the future.
Management believes that these non-GAAP financial measures assist
in providing a more complete understanding of the Company's
underlying operational results and trends, and in allowing for a
more comparable presentation of results. Management uses these
measures along with their corresponding GAAP financial measures to
help manage the Company's business and to help evaluate DUSA's
performance compared to the marketplace. However, the presentation
of non-GAAP financial measures is not meant to be considered in
isolation or as superior to or as a substitute for financial
information provided in accordance with GAAP. The non-GAAP
financial measures used by the Company may be calculated
differently from, and, therefore, may not be comparable to,
similarly titled measures used by other companies. Investors are
encouraged to review the reconciliations of these non-GAAP
financial measures to the comparable GAAP results, contained in the
table below. Three-months ended Nine-months ended September 30,
September 30, 2009 2008 2009 2008 (Unaudited) (Unaudited)
(Unaudited) (Unaudited) GAAP net loss $(415,240) $(2,836,855)
$(2,874,880) $(4,259,787) Stock-based compensation (a) 207,178
353,262 631,770 1,042,812 Payment on acquisition (b) - 1,500,000 -
1,500,000 Consideration to former Sirius shareholders (c) 5,000 -
310,000 - Change in fair value of warrants (d) (24,051) (651,767)
37,679 (775,636) Non-GAAP adjusted net loss $(227,113) $(1,635,360)
$(1,895,431) $(2,492,611) Non-GAAP basic and diluted net loss per
common share $(0.01) $(0.07) $(0.08) $(0.10) Weighted average
number of common shares 24,108,908 24,078,610 24,099,786 24,078,546
(a) Stock-based compensation expense resulting from the application
of SFAS 123(R). (b) Milestone payment related to Sirius
Laboratories acquisition. (c) Payment of $100,000 and accrual of
$210,000 related to the release, consent and the third amendment to
the merger agreement between DUSA and the former Sirius
shareholders. (d) Non-cash gain/loss on change in fair value of
warrants. Conference Call Details and Dial-in Information In
conjunction with this announcement, DUSA will host a conference
call today: Friday, November 6th - 8:30 a.m. Eastern If calling
from the U.S. or Canada use the following toll-free number:
800.647.4314 Password - DUSA For international callers use
502.498.8422 Password - DUSA A recorded replay of the call will be
available approximately 15 minutes following the call U.S. or
Canada callers use 877.863.0350 International callers use
858.244.1268 The call will be accessible on our web site
approximately six hours following the call at
http://www.dusapharma.com/. About DUSA Pharmaceuticals DUSA
Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical
company focused primarily on the development and marketing of its
Levulan® PDT technology platform, and complementary dermatology
products. Levulan® PDT is currently approved for the treatment of
Grade 1 and 2 actinic keratoses of the face and scalp. DUSA also
markets other dermatology products, including ClindaReach®. DUSA is
researching the use of broad area Levulan® PDT to treat AKs and
prevent squamous cell carcinomas in immunosuppressed solid organ
transplant recipients and is supporting research related to oral
leukoplakia in collaboration with the National Institutes of
Health. DUSA is based in Wilmington, Mass. Please visit our web
site at http://www.dusapharma.com/. Except for historical
information, this news release contains certain forward-looking
statements that represent our current expectations and beliefs
concerning future events, and involve certain known and unknown
risk and uncertainties. These forward-looking statements relate to
Levulan's growth potential, expectations for filing an amendment to
a regulatory application, and management's beliefs concerning
non-GAAP financial measures. These forward-looking statements are
further qualified by important factors that could cause actual
results to differ materially from future results, performance or
achievements expressed or implied by those in the forward-looking
statements made in this release. These factors include, without
limitation, actions by health regulatory authorities, changing
economic conditions, launch of competitive products, the status of
our patent portfolio, reliance on third parties, sufficient
funding, and other risks and uncertainties identified in DUSA's
Form 10-K for the year ended December 31, 2008. DATASOURCE: DUSA
Pharmaceuticals, Inc. CONTACT: Robert F. Doman, President &
CEO, +1-978-909-2216, or Richard Christopher, VP Finance & CFO,
+1-978-909-2211, or Chad Rubin, Investor Relations, The Trout Group
LLC, +1-646-378-2947 Web Site: http://www.dusapharma.com/
Copyright